By Accelerating New Drug Development and Employing New Online Platforms Sales of New Drugs Marketed over Past Three Years Double…
Search Results: Tot Biopharm (96)
Seizes Opportunities from Industry Policies to Pursue Strategic Transformation Accelerates New Drug Development and Builds Internet Ecosystem Revenue from New…
RedHill Biopharma Ltd (Nasdaq: RDHL), a specialty biopharmaceutical company, today announced that the U.S. Phase 2 study with opaganib (Yeliva®,…
Revenue Increases by 1.0% to RMB12.648 Billion Underlying Profit up 5.2% to RMB1.761 Billion Sino Biopharmaceutical Limited (“Sino Biopharm” or…
Revenue was approximately RMB6.22 Billion; Profit Attributable to Owners of the Parent was approximately RMB862 Million Sino Biopharmaceutical Limited (“Sino…
Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative R&D driven pharmaceutical conglomerate in the PRC, has announced that the new…
Revenue Climbs 16.0% to RMB24.23 billion Underlying Profit Up 10.2% to RMB3.13 billion; Achieves an outstanding R&D performance and obtains…
Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading and innovation-driven pharmaceutical…
Revenue Up 33.4% to RMB6,208 Million Underlying Profit* Climbs 22.4% to RMB976 Million Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the…
Revenue Up 41% to RMB20.9 Billion and Net Profit Climbs 317% to RMB9 Billion HONG KONG – (ACN Newswire) – Sino Biopharmaceutical Limited…
Profit Attributable to the Group Increased by Approximately 29.9% to Approximately RMB 2,247,477,000 HONG KONG – (ACN Newswire) – Sino Biopharmaceutical…
— NVK002 completed patient recruitment for both concurrent Phase III clinical trials significantly ahead of schedule — First commercialized product,…
HONG KONG — Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or the “Group”, Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical…
On 27 March 2024, Fosun International (HKG: 0656) announced its 2023 annual results. During the Reporting Period, Fosun’s total revenue…
Northway Group is embarking on a project to establish Europe’s largest biotechnology hub, BIO CITY, in Vilnius, the capital of…
The World Bank recently released its updated Global Economic Outlook report, projecting a 2.1% global economic growth for 2023. This…
Sihuan Pharmaceutical Holdings Group Ltd. (the Company or Sihuan Pharmaceutical, together with its subsidiaries, the Group, HKG: 0460) is pleased…
Following pioneering breakthroughs in basic science, companies are often needed to carry out technological innovation and commercialization to turn scientific…
I In March this year, Guo Guangchang, Chairman of Fosun International, used the “perfect storm” as a metaphor for Fosun’s…
Medical aesthetic segment achieved a revenue of RMB194.0 million Returned to high growth Significant R&D investment continued to effectively facilitate…